CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors

Peking University Cancer Hospital & Institute15 enrolled

Overview

The objective of the study is to construct a noninvasive approach 68Ga-ACN376 PET/CT to detect the CLDN18.2 expression of tumor lesions in patients with Solid tumors and to identify patients benefiting from CLDN18.2 targeting treatment.

Study Type

INTERVENTIONAL

Allocation

Purpose

SCREENING

Masking

NONE

Enrollment

Conditions

Solid Tumor

Interventions

18F-FDGDRUG

All study participants will undergo one 18F-FDG PET/CT scan.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 1\. Aged \>18 years old; ECOG 0 or 1; * 2\. Patients with solid tumors; * 3\. Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1); * 4\. life expectancy \>=12 weeks. Exclusion Criteria: * 1\. Significant hepatic or renal dysfunction; * 2\. Is pregnant or ready to pregnant; * 3\. Cannot keep their states for half an hour; * 4\. Refusal to join the clinical study; * 5\. Suffering from claustrophobia or other mental diseases; * 6\. Any other situation that researchers think it is not suitable to participate in the experiment.

Locations (1)

Beijing cancer hospital

Beijing, Beijing Municipality, China

RECRUITING

Outcomes

Primary Outcomes

Standardized uptake value（SUV）

SUV is a semi-quantitative analysis index to describe the radioactive uptake of lesions, which has certain reference value for differentiating benign and malignant lesions。 The uptake of the tracer （68Ga-ACN376） in solid tumor lesions by measuring SUV on PET/CT.

Time frame: 2 years

Central Contacts

Hua Zhu

CONTACT

010-88196495 zhuhuabch@pku.edu.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.